Previous Article | Next Article ![]()
Journal of Bacteriology, February 2009, p. 922-930, Vol. 191, No. 3
0021-9193/09/$08.00+0 doi:10.1128/JB.01350-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
,
Department of Environmental Science and Protein Research Center for Bio-Industry, Hankuk University of Foreign Studies, Yongin, Kyunggi-Do 449-791,1 Department of Environmental Medical Biology and Institute of Tropical Medicine, the Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 120-752, South Korea2
Received 29 September 2008/ Accepted 9 November 2008
|
|
|---|
|
|
|---|
Cyclic 3',5'-AMP (cAMP) is a cellular signaling metabolite that is involved in relieving the carbon catabolite repression of many genes and operons that encode diverse catabolic enzymes (10). It also mediates multiple global regulatory networks by controlling the expression of major transcription factors in a variety of microorganisms (4, 11). For example, bacterial global regulators such as sigma factor S (RpoS) or ferric uptake regulator (Fur) have been shown to be regulated by cAMP complexed with another global regulator, cAMP receptor protein (CRP), which is itself regulated by cAMP (9, 13, 20). Recently, the cAMP-CRP complex has been reported to be involved in the regulation of numerous virulence factors in pathogenic bacteria. The production of the potent virulence factors of pathogenic Vibrio species, cholera toxin (ctxAB) and toxin-coregulated pilus (tcpPH) in Vibrio cholerae (31) and metalloprotease (vvpE) and cytolytic hemolysin (vvhBA) in V. vulnificus (2, 8, 14), has been shown to be regulated by the cAMP-CRP complex. Thus, it has been suggested that cAMP is one of the key molecules for the timely expression of virulence factors in pathogenic bacteria (10).
Microorganisms are required to modulate cAMP levels to mediate various cellular processes in response to physiological demands (19). The final intracellular concentration of cAMP is determined by a fine-tuned regulatory system that includes its synthesis by adenylate cyclase, its extracellular excretion, and its cleavage into 5'-AMP by 3',5'-cAMP phosphodiesterase (5, 28). Although we have extensive knowledge about the synthesis and excretion of cAMP (5), the enzymatic hydrolysis of cAMP and the genes encoding these enzymes have been studied in only a limited number of bacterial species. The genes encoding the cytoplasmic 3',5'-cAMP phosphodiesterase (CpdA) have been isolated and characterized for only two bacterial species so far, Escherichia coli (12) and Haemophilus influenza (23). Studies of some bacterial species, including E. coli (12), Salmonella enterica serovar Typhimurium (4), Bradyrhizobium japonicum (7), and Myxococcus xanthus (18), indicate that the CpdA proteins are involved in decreasing intracellular cAMP levels. The regulation of cpdA expression, however, has not yet been studied.
We have isolated the cpdA gene from the genomic library of V. vulnificus (GenBank accession number AY221025) (20). When the putative amino acid sequence of V. vulnificus CpdA was aligned with those deduced from the corresponding genes of E. coli (GenBank accession number BAA03986.1) and H. influenzae (GenBank accession number NP_438561.1), it showed significant identities of 51 and 45%, respectively (see Fig. S1 in the supplemental material). In the present study, we investigated the role of this gene product in determining intracellular cAMP levels and examined the regulation of cpdA gene expression in V. vulnificus.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Strains and plasmids used in this study
|
cya and
cpdA mutant V. vulnificus strains were grown in LBS. The
cpdA mutant carrying either a broad-host-range vector (pLAFR5) (16) or cpdA-containing pLAFR5 (pHS51) was grown in LBS supplemented with 3 µg/ml tetracycline. Exponential-phase (the optical density at 595 nm [OD595] ranged from 0.6 to
0.7) and stationary-phase (the OD595 ranged from 3.3 to
4.0) cells were harvested and lysed, and the amount of cAMP in the lysates was estimated using the cAMP Biotrak enzyme immunoassay system according to the manufacturer's instructions (Amersham). To determine concentrations of secreted cAMP, the same procedure was applied to cell-free spent medium, which had been filtered through a 0.22-µm-pore-size membrane.
Western blot analysis of CpdA.
A pair of oligonucleotides, cpdAexp-F (5'-CCCGGATCCTTGCAACATACATCCAGTGATACG-3' [underlined sequence indicates a BamHI restriction site]) and cpdAexp-R (5'-GGGCTGCAGTTAGGACGGCTCATATCAGTAACC-3' [underlined sequence indicates a PstI restriction site]), were used to amplify an 840-bp DNA fragment containing the full sequence of the cpdA open reading frame (ORF) from the genomic DNA of V. vulnificus. Recombinant CpdA (rCpdA) was overexpressed in E. coli JM109 cells carrying pQE30-cpdA with His6-tagged CpdA and purified using a Ni-nitrilotriacetic acid affinity column as directed by the manufacturer (Qiagen). Purified rCpdA was used to generate polyclonal antibodies by three immunizations of Sprague-Dawley rats (200 µg of CpdA protein per immunization) at 3-week intervals. Cell lysates of wild-type and
cpdA, crp, and
cya mutant V. vulnificus were prepared by sonication in TNT buffer (10 mM Tris-HCl, 150 mM NaCl, and 0.05% [vol/vol] Tween 20 [pH 8.0]) (29). One hundred micrograms of each bacterial lysate was fractionated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and transferred onto a Hybond P membrane (Amersham). The membrane was incubated with polyclonal antibodies against rCpdA (1:5,000 dilution) and then incubated with alkaline phosphatase-conjugated rabbit anti-rat immunoglobulin G (1:5,000; Sigma). Immunoreactive protein bands were visualized using a nitroblue tetrazolium-BCIP (5-bromo-4-chloro-3-indolylphosphate) system (Promega). To investigate the effect of added cAMP on CpdA levels, cAMP was added to the
cya mutant at a final concentration of 1.0 mM for 1.5 h before extracts were prepared.
Northern blot analysis.
Total RNA was extracted from wild-type V. vulnificus ATCC 29307 cells using Trizol reagent (Gibco BRL) according to the manufacturer's instructions and quantified by spectrophotometric readings at 260 nm. Thirty micrograms of RNA was fractionated by 1% formaldehyde agarose gel electrophoresis in a running buffer (0.1 M MOPS [morpholinepropanesulfonic acid], 40 mM sodium acetate, and 5 mM EDTA), blotted onto a Hybond-N membrane (Amersham) by capillary transfer in 20x SSPE (3 M NaCl, 0.2 M NaH2PO4, 0.02 M EDTA), and immobilized using a UV cross-linker (CL-1000; UVP). Blots were incubated for 2 h at 42°C in a prehybridization solution (5x SSPE, 50% formamide, 5x Denhardt's solution, 0.5% SDS, 200 µg/ml salmon sperm DNA, and 10% dextran sulfate). Hybridization at 42°C was continued overnight in the presence of a labeled cpdA probe. For the preparation of the probe, cpdA gene-containing plasmid pINE45 was digested with EcoRI and HindIII, and the 1.7-kb inserted DNA fragment was isolated using the GeneClean kit (Bio101) and labeled with [
-32P]ATP using a Random Primer kit (Takara). The membrane was washed twice with 2x SSPE-0.1% SDS at room temperature for 15 min and twice with 0.1x SSPE-0.5% SDS at 60°C for 30 min and then exposed to X-ray film (29).
Primer extension analysis.
A primer, yqiE-R (5'-TTCGATCACATTGCTCCACC-3'), was designed to be complementary to positions –976 to –956 with respect to the initiation codon (IC) of cpdA. The primer was labeled at the 5' terminus with [
-32P]ATP using T4 polynucleotide kinase (Takara), annealed to 150 µg RNA in hybridization buffer (10 mM Tris-HCl, 1 mM EDTA, 1.25 M KCl [pH 8.0]), and then incubated at 65°C for 3 min. RNA was converted to cDNA with SuperScript II reverse transcriptase (Invitrogen). The resultant cDNA products were precipitated and resolved on a sequencing gel beside sequencing ladders generated with the same primer used for primer extension. The sequence of pINE45-1 was determined using the dideoxy chain termination method using AccuPower DNA sequencing kit (Bioneer) as previously described (27). Sequencing gels were dried and then visualized with a phosphorimager (Personal Molecular Imager FX; Bio-Rad).
Complementation of the cpdA gene.
An intact cpdA gene was isolated as EcoRI and HindIII from pINE45, a pUC19-based plasmid with a 1.72-kb Sau3AI fragment of V. vulnificus ATCC 29307 genomic DNA including the coding sequence of cpdA. The cpdA-containing DNA fragment was cloned into EcoRI- and HindIII-digested pLAFR5 to produce pHS51. The resultant plasmid in E. coli SM10
pir was transferred into the
cpdA mutant (HY101) (20) by conjugation, and exconjugants were selected on TCBS (thiosulfate-citrate-bile salts-sucrose) agar containing tetracycline.
Construction of the cpdA::luxAB transcriptional reporter fusions. A set of cpdA::luxAB fusions was made by subcloning DNA fragments encompassing upstream regions of the cpdA gene into pHK0011, which contains promoterless luxAB genes (8). To construct a transcriptional fusion, pSMK-cpdA-1, a DNA fragment containing the whole upstream region of the cpdA gene up to the 3' end of the tolC gene, was obtained by PCR using primers SMK-F1K (5'-GCGGTAATAAGGTACCACGG-3' [underlining indicates a KpnI site]) and SMK-RX-1 (5'-GCTCTAGAATACTGTTCTCGCTGAGCG 3' [underlining indicates an XbaI site]), digested with KpnI and XbaI, and ligated into KpnI/XbaI-digested pHK0011. The resulting plasmid includes the region from positions –1,521 to +41 relative to the IC of V. vulnificus cpdA. The PCR product amplified with primers SMK-F2K (5'-GGGGTACCGTCCAGTTGTGCAATAAATG-3' [underlining indicates a KpnI restriction site]) and SMK-RX (5'-AGAACCTCTAGATCTTCTGG-3' [underlining indicates an XbaI restriction site]) was cloned into pHK0011 to produce pSMK-cpdA2, which includes only the intergenic space between tolC and mutT (positions –1178 to –1051 relative to the cpdA IC). pSMK-cpdA3 was constructed by inserting the DNA encompassing positions –1163 to –1051 relative to the cpdA IC that was amplified using SMK-F3K (5'-GGGGTACCAAATGAATTGTTTAAACCTAAA-3' [underlining indicates a KpnI restriction site]) and SMK-RX.
The cpdA::luxAB reporters were then mobilized into the wild type and the
cpdA, crp, and
cya V. vulnificus mutants via conjugal transfer. Cultures of bacterial cells grown overnight (16 to 18 h) that contained the reporters were inoculated into fresh LBS medium with tetracycline (3 µg/ml) and grown to stationary phase. At various time points, a portion of the samples was diluted 100-fold with LBS medium. Expression from various lengths of the cpdA upstream region was measured by monitoring light production in the presence of 0.006% (vol/vol) n-decyl aldehyde using a luminometer (TD-20/20; Turners Designs). Light production was expressed in arbitrary relative light units (RLU), and the specific bioluminescence was calculated by normalizing RLU with cell mass (OD595) as described previously (26). cAMP at concentrations up to 1.0 mM was added exogenously to the
cya mutant culture, and light emission was monitored.
Site-directed mutagenesis of the cpdA promoter. Based on the CRP-binding consensus sequence (AAATGTGATCTAGATCACATTT) (6), a putative CRP-binding site, 5'-AGTTGTGCAATAAATGAATTGT-3', was found in the upstream region of the promoter for the mutT-yqiB-cpdA-yqiA operon. This site was mutagenized using the GeneEditor in vitro site-directed mutagenesis kit (Promega). Briefly, a DNA fragment containing the cpdA promoter region in pSMK-cpdA2 (see above) was cloned into pGEM-11zf(+) to produce pGEM-11zf(+)-cpdA2. Next, cpdA-siteF (5'-GGGGTACCGTCCCGTAAAACAAAAAATGAATTGTTTAAACC-3' (underlining indicates the r mutagenesis site, and italics indicate a KpnI site]) was used to substitute six bases in the putative CRP-binding site. The resultant plasmid was named pGEM-11zf(+)-cpdA2mt. The insert DNA of pGEM-11zf(+)-cpdA2mt was isolated after digestion with KpnI and XbaI and inserted into pHK0011 to produce pSMK-cpdA2mt.
Electrophoretic mobility shift assay.
The V. vulnificus rCRP protein was overexpressed in E. coli BL21 carrying pHK0201 (15), a pRSETA (Invitrogen)-based expression plasmid, and purified by Ni-nitrilotriacetic acid affinity chromatography according to the manufacturer's instructions (Qiagen). The 373-bp upstream region of the mutT gene was PCR amplified using SMK-F1K and SMK-R2X (5'-GCTCTAGACTCAAAGGACATTGCTC-3') and labeled with [
-32P]ATP using T4 polynucleotide kinase. The labeled DNA fragment (225 nM) was incubated with various concentrations of purified rCRP protein (50 to
200 nM) for 30 min at 37°C in a 20-µl reaction mixture containing 1x binding buffer (26) with 500 µM cAMP (Sigma). Following the addition of 3 µl of loading buffer, the samples were separated on a 6% nondenaturing polyacrylamide gel. For competition analyses, the identical but unlabeled sequence was included as a competitor. Competitor DNA from 22.5 to 675 nM was added to reaction mixtures containing 225 nM of labeled DNA prior to the addition of 200 nM CRP. A 378-bp DNA fragment encompassing the promoter of the gap gene, encoding glyceraldehyde-3-phosphate dehydrogenase, was amplified from V. vulnificus genomic DNA using primers gap-F (5'-CATTAATCTAGATATCGTCG-3') and gap-R (5'-AATCAGTGGATCCAAAGCGC-3') and included as nonspecific DNA in the binding assay.
|
|
|---|
![]() View larger version (14K): [in a new window] |
FIG. 1. Genetic organization and transcription of the mutT-yqiB-cpdA-yqiA operon in V. vulnificus. (A) Based upon the genetic organization of the cpdA gene, two different cpdA::luxAB transcriptional fusions were constructed: one (pSMK-cpdA2) includes the upstream region of mutT, the first gene of the tentative operon, and the other (pSMK-cpdA-1) includes the entire upstream region of cpdA. (B) For Northern blot analysis of cpdA mRNA, total RNA extracted from stationary-phase V. vulnificus cells was hybridized with a 32P-labeled cpdA probe and visualized by autoradiography. The left lane (lane 1) is ethidium bromide-stained total RNA from wild-type V. vulnificus in a formamide agarose gel, and the right lane (lane 2) is a Northern hybridization using the cpdA probe. Arrows and numbers on the left side indicate the molecular sizes of 23S and 16S RNAs in kilobases (kb). (C) Wild-type V. vulnificus carrying each fusion or the vector only (pKH0011) was grown in LBS medium supplemented with 3 µg/ml tetracycline, aliquots were sampled, and their cell masses (OD595) and their bioluminescence (RLU) were determined. Luciferase activities are expressed as normalized values that were obtained by dividing the RLU by the OD595 of each sample. The averages of three independent experiments are shown, along with their standard deviations.
|
The transcription start site for the mutT-yqiB-cpdA-yqiA operon was determined by primer extension (Fig. 2A) to be at position –22 relative to the IC of mutT (Fig. 2B). The putative promoter showed the presence of relatively well-conserved –10 and –35 regions (TAAACT and TTGAGT, respectively). In addition, a sequence homologous to the CRP-binding consensus sequence (5'-AAATGTGATCTAGATCACATTT-3') (6) was discernible at position –95.5 relative to the transcription start site.
![]() View larger version (17K): [in a new window] |
FIG. 2. Determination of the transcriptional start site of the cpdA gene. (A) Primer extension using V. vulnificus RNA and oligonucleotide primer yqiE-R (annealing to positions +130 to +150 relative to the IC of mutT). Lanes C, T, A, and G represent sequencing ladders of pINE45-1. The +1 indicates the site of transcriptional initiation. (B) Sequence of the upstream region of mutT, the first gene of the operon composed of mutT, yqiB, cpdA, and yqiA. The initiation codon for mutT is in boldface type, and the promoter and the putative –10 and –35 regions are underlined. The putative binding site for the cAMP-CRP complex is designated with a box. The primers used for the construction of the cpdA::luxAB transcription fusions are indicated with horizontal arrows.
|
cpdA mutant (20) was compared to that of the wild-type strain and a
cya mutant deficient in the cAMP-synthesizing enzyme adenylate cyclase. The intracellular concentrations of cAMP in wild-type cells grown in LBS medium at exponential and stationary phases were 26 and 6.3 pmol/mg protein, respectively (Table 2). The
cya mutant had nondetectable levels of cAMP in both growth phases. In contrast, the
cpdA mutant showed highly elevated levels of cellular cAMP, estimated at 99 to
137 and 37 to
45 pmol/mg protein from exponential- and stationary-phase cells, respectively. When the intact cpdA gene was introduced into the
cpdA mutant on the multicopy plasmid pHS51, its intracellular cAMP level decreased to below the detection limit. |
View this table: [in a new window] |
TABLE 2. Intracellular cAMP contents in various V. vulnificus strains grown in LBS medium
|
cpdA mutant cultures was also determined. Spent medium sampled from the
cpdA mutant culture showed a 1.7-fold-higher concentration of cAMP than that of the wild type (S.-M. Kim and K.-H. Lee, unpublished data). This implied that the higher intracellular cAMP level in the
cpdA mutant was not from a reduced excretion of cAMP but possibly from an absence of cAMP phosphodiesterase activity. Therefore, this suggests that CpdA controls the level of intracellular cAMP through degradation.
Contents of CpdA in wild-type,
cya mutant, and crp mutant V. vulnificus strains.
Since V. vulnificus CpdA appears to degrade cellular cAMP via a cAMP phosphodiesterase activity, as is seen in other bacteria (12, 23), the effect of the substrate cAMP on the level of the CpdA protein was examined. Western blotting using polyclonal anti-CpdA antibodies produced an immunoreactive band of
30.5 kDa in all V. vulnificus strains except the
cpdA mutant (Fig. 3A). Interestingly, the
cya mutant, which does not contain detectable levels of cAMP (Table 2), showed significantly decreased levels of CpdA compared to those of the wild type. Densitometric quantification of immunoreactive bands indicated about a threefold decrease in levels in the
cya mutant (Fig. 3B). This suggested that cAMP may play a role in inducing the production of an enzyme that uses cAMP as a substrate. cAMP induction is known to be associated with CRP (19), so the CpdA content was also measured in a V. vulnificus crp mutant. The crp mutant showed a CpdA level similar to that of the
cya mutant. In addition, the crp
cya double mutant showed essentially the same pattern as that of each single mutant (data not shown), which suggested that cpdA expression is activated by the cAMP-CRP complex.
![]() View larger version (14K): [in a new window] |
FIG. 3. Cellular contents of the cAMP phosphodiesterase (CpdA) in wild-type (wt), crp mutant, and cya mutant strains of V. vulnificus. (A) Lysates of V. vulnificus strains grown to stationary phase (OD595 of 1.5) were used to estimate CpdA levels by Western blotting. One hundred micrograms of each bacterial lysate was fractionated by SDS-polyacrylamide gel electrophoresis. The blotted membrane was incubated with polyclonal antibodies raised against the recombinant CpdA and then incubated with alkaline phosphatase-conjugated rabbit anti-rat immunoglobulin G. Upon incubation with the nitroblue tetrazolium-BCIP system, the CpdA protein appeared as an immunoreactive band as indicated by an arrow. (B) The intensities of bands corresponding to CpdA were estimated by densitometry, and the densitometric readings are presented in the plot as values relative to those of CpdA of the wild-type strain.
|
cya and crp mutants contained less CpdA protein than did the wild type (Fig. 3), the effect of cAMP on cpdA gene expression was further confirmed using a transcriptional reporter fusion. The cpdA::luxAB transcriptional fusion pSMK-cpdA2 showed reduced levels of expression in the
cya or crp mutant, which were about three- to fourfold lower than the levels of expression in the wild type (Fig. 4). The degree of the decrease in the level of transcription fusion expression in the
cya or crp mutant was similar to the extent of the decrease in the level of the CpdA protein in the same mutants as shown in Fig. 3.
![]() View larger version (10K): [in a new window] |
FIG. 4. Effects of crp or cya mutations on expression of cpdA::luxAB transcription fusion. Wild-type (wt), crp, and cya V. vulnificus strains carrying pSMK-cpdA2 were grown to stationary phase in LBS medium supplemented with 3 µg/ml tetracycline, and aliquots were sampled and measured for cell mass (OD595) and bioluminescence (RLU). Luciferase activities are expressed as normalized values by dividing the RLU by the OD595 of each sample. The activities of two independent experiments were averaged and are shown with their standard deviations. An asterisk indicates P values less than 0.005.
|
cya mutant was caused by the absence of cAMP, various concentrations of cAMP were added, and the level of expression of pSMK-cpdA2 was measured after 1.5 h (Fig. 5A). The level of expression increased in a dose-dependent manner, with maximal expression observed in the
cya mutant incubated with
0.5 mM cAMP. In a subsequent experiment, cAMP was exogenously added to the
cya mutant carrying pSMK-cpdA2. In the presence of 1.0 mM cAMP in the medium, the mutant expressed the fusion at increasingly higher rates than the control in a time-dependent manner, peaking at 2 h after the addition of cAMP (Fig. 5B). Similarly, 1.0 mM cAMP was exogenously added to either the wild type or the
cya mutant, and their cellular levels of CpdA protein were compared. A Western blot using polyclonal antibodies against rCpdA showed that the wild type was not influenced by the exogenous addition of cAMP, but the
cya mutant showed higher levels in the presence of added cAMP (Fig. 5C). All of the above-described results suggest that the cellular amount of CpdA is regulated at the transcriptional level via cAMP-CRP complex-mediated activation.
![]() View larger version (16K): [in a new window] |
FIG. 5. Expression of cpdA in the cya mutant V. vulnificus strain in the presence of exogenous cAMP. (A) Various concentrations of cAMP ranging from 0 to 1.5 mM were added to the cya strain carrying pSMK-cpdA2 freshly grown in LBS medium supplemented with 3 µg/ml tetracycline. After a 1.5-h incubation, specific bioluminescence was estimated as described in the legend of Fig. 4. (B) The cya strain carrying pSMK-cpdA2 was grown in LBS medium supplemented with 3 µg/ml tetracycline, and half of the culture was treated with 1.0 mM cAMP at the time point indicated by a vertical arrow. Growth and luminescence of the mutant in the presence or absence of exogenously added cAMP were compared. Luciferase activities are expressed as described in the legend of Fig. 4. (C) Wild-type (wt) and cya cells in exponential phase were treated with 1.0 mM cAMP for 1.5 h and used for Western blot analysis to measure the contents of CpdA, as described in the legend of Fig. 3. Lane 1, wild type without cAMP; lane 2, wild type with cAMP; lane 3, cya strain without cAMP; lane 4, cya strain with cAMP.
|
![]() View larger version (6K): [in a new window] |
FIG. 6. Binding of the cAMP-CRP complex to the upstream region of the mutT-yqiB-cpdA-yqiA operon. A gel shift assay was performed to determine the direct interaction between cAMP-CRP and the upstream region of the mutT gene. A 32P-labeled 373-bp DNA probe of the upstream region (225 nM) was incubated with increasing amounts of CRP up to 200 nM in the presence of cAMP (1.0 mM). The reaction mixtures were then subjected to 6% native polyacrylamide gel electrophoresis. For competition analysis, the same, but unlabeled, 373-bp DNA was included. As noncompetitive and nonspecific DNA, an unlabeled 378-bp DNA fragment containing the promoter of the gap gene (Pgap) was added in excess. Lane 1, probe only; lane 2, probe with 50 nM CRP; lane 3, probe with 75 nM CRP; lane 4, probe with 100 nM CRP; lane 5, probe with 150 nM CRP; lane 6, probe with 200 nM CRP; lane 7, probe with 200 nM CRP and 22.5 nM unlabeled upstream DNA; lane 8, probe with 200 nM CRP and 225 nM unlabeled upstream DNA; lane 9, probe with 200 nM CRP and 675 nM unlabeled upstream DNA; lane 10, probe with 200 nM CRP and 200 nM unlabeled Pgap DNA. The arrow on the left side indicates the unbound DNA probe, whereas the arrow on the right side indicates the DNA bound with CRP.
|
![]() View larger version (13K): [in a new window] |
FIG. 7. Effect of mutating the putative CRP binding site on cpdA expression. (A) A putative CRP-binding site, based upon the conserved nucleotide sequences for CRP binding in E. coli (6), was found in the upstream region of mutT centered at position –95.5 upstream of the transcription start site (designated with a +1) and indicated as an open box in the pSMK-cpdA2 fusion. The same transcription fusion with an altered putative CRP-binding site, pSMK-cpdA2mt, was constructed by site-directed mutagenesis to change the nucleotides as shown in B (hatched box). The upstream region of mutT in pSMK-cpdA3 has a deletion of the first 11 of the 22 nucleotides that comprise the putative CRP-binding site. Wild-type, crp, and cya strains carrying pSMK-cpdA2mt (C) or pSMK-cpdA3 (D) were grown in LBS medium supplemented with 3 µg/ml tetracycline, and aliquots were sampled to estimate specific luciferase activities. Luciferase activities are expressed as described in the legend of Fig. 4. (E) Assay of binding of the cAMP-CRP complex to the DNA fragments carrying the original sequence (wt probe) (the same DNA used in Fig. 6) or the mutagenized sequence (mt probe) (as indicated in B) was performed as described in the legend of Fig. 6. Lane 1, wild-type probe without CRP; lane 2, wild-type probe with 200 nM CRP; lane 3, mutagenized probe without CRP; lanes 4, 5, and 6, mutagenized probe with 20, 100, and 200 nM CRP, respectively. The arrow on the left side indicates the unbound DNA probe, whereas the arrow on the right side indicates the DNA bound with CRP.
|
cya strains (Fig. 7C and D) compared to the level of pSMK-cpdA2 expression in the crp and
cya strains. In addition, to verify if cAMP-CRP binding to this putative site occurs, the DNA fragment used in Fig. 6 and the same DNA but with the mutagenized putative CRP-binding site were used for electrophoretic mobility shift assays. No binding of cAMP-CRP to the mutagenized probe was observed (Fig. 7E, lanes 3 to 6), while the wild-type probe was efficiently bound by the cAMP-CRP complex (Fig. 6 and 7E, lanes 1 to 2). These results suggest that cpdA expression is activated by cAMP-CRP acting on the region between positions –106 and –85 relative to its transcription start site. |
|
|---|
Bacterial cells grown in LB-based media without the sugars transported by phosphotransferase systems such as glucose did not exhibit maximal cAMP levels when they entered stationary phase (20, 22). cAMP levels in V. vulnificus have been estimated to be approximately 20 to
50 pmol cAMP/mg of protein in the exponential phase, decreasing to about 5 pmol cAMP/mg of protein in stationary phase (20) (Table 2). When V. vulnificus was deficient in cAMP phosphodiesterase (CpdA), it showed highly elevated levels of cAMP compared to those of an isogenic wild-type strain during both exponential and stationary phases (Table 2). The increased level of cAMP in the
cpdA mutant has also been confirmed by measuring gene expression, which is tightly regulated by cAMP and thus might serve as an index of the intracellular level of cAMP. For example, the rpoS gene, encoding V. vulnificus sigma factor S, is known to be repressed by cAMP (20). We found approximately twofold-lower levels of expression of the rpoS gene in the
cpdA mutant than in the wild type (20). When the
cpdA mutant was supplied with the intact cpdA gene, its cAMP level was too low to be detected, similar to the
cya mutant that lacks adenylate cyclase activity (Table 2). Therefore, CpdA appears to be an important factor in controlling the intracellular concentration of cAMP in V. vulnificus.
The expression of many enzymes is induced by the presence of their substrate molecules (33). This regulatory pattern for catalytic enzymes prompted us to study the effect of cAMP on the regulation of cpdA expression. cpdA expression at the transcriptional level was activated by the cAMP-CRP complex (Fig. 3 and 4). The regulatory region for cpdA includes a sequence homologous to the E. coli CRP consensus sequence (Fig. 2B), and we found that this sequence was bound by the cAMP-CRP complex (Fig. 6 and 7). This site is from positions –106 to –85 (centered at position –95.5) with respect to its transcription start site, which is considered an activation site for class III CRP-dependent promoters such as the araBAD promoter (33). Class III promoters have been reported to require a secondary regulator protein (e.g., the AraC protein for the araBAD promoter) for maximal induction. Regulation at class III promoters was also reported to involve the formation of a DNA loop (21).
Exponential-phase cells growing in LBS medium contained higher cAMP contents (Table 2), possibly due to a lowered expression or reduced activity of CpdA during this growth phase. Thus, it is required to search and identify another regulator for cpdA transcription and its possible interaction with the cAMP-CRP complex for optimal cpdA expression in V. vulnificus, as shown in the araBAD promoter (33). It is also possible that the presence of other factors acting at the posttranscriptional level finely adjusts the CpdA protein content or its enzymatic activity.
Both the Northern blot and primer extension experiments clearly suggest that the cpdA gene is organized as an operon with its upstream flanking genes mutT and yqiB as well as its downstream gene yqiA (Fig. 1 and 2). MutT is the nucleoside triphosphate pyrophosphohydrolase that catalyzes a conversion of deoxynucleoside triphosphate to deoxynucleoside monophosphate (3). The predicted gene products of yqiB and yqiA have homology to a hypothetical phosphohydrolase from Vibrio parahaemolyticus (GenBank accession no. ZP_01993039.1) and a hypothetical esterase from Yersinia pestis (GenBank accession no. NP_404305.1), respectively. Their functions, however, have not been determined. Thus, it is currently not known why the cpdA gene, which encodes an enzyme to catalyze the conversion of cAMP to AMP, is coregulated and coexpressed with the other three genes, although the gene products from this operon might be involved in the metabolism of nucleotides to produce nucleoside monophosphates or to remove undesired nucleotides. Further study is needed to elucidate their biological significance.
Cyclic phosphodiesterases have been shown to be involved in the stress response of M. xanthus against temperature and osmotic shocks (18). The
cpdA mutant V. vulnificus strain shows additional phenotypes. For example, scanning electron microscopy of wild-type and
cpdA mutant V. vulnificus strains revealed that the cpdA gene product is required for normal cellular morphology (see Fig. S2 in the supplemental material). The elongated morphology of the
cpdA mutant might result from altered expression of the genes involved in cell division and/or cell shape caused by a failure to adjust cAMP levels (4, 5). In addition, proteomic screening of V. vulnificus proteins required for mature biofilm formation found many proteins whose levels of expression are expected to be regulated by the cAMP-CRP complex (17). These results imply that deficiency in functional CpdA results in pleiotropic effects on the pathogenic bacterium V. vulnificus. According to data described previously by Merrell et al. (24), cpdA is one of the most important colonization factors in V. cholerae. Therefore, it will be interesting to investigate the roles of CpdA in the pathogenesis of V. vulnificus.
We thank Songhee H. Kim for isolating plasmid pINE45 and Hyuk-Soon Ihm for isolating plasmid pINE45-1.
Published ahead of print on 21 November 2008. ![]()
Supplemental material for this article may be found at http://jb.asm.org/. ![]()
|
|
|---|
S in survival of exponential phase cells under oxidative stress. J. Bacteriol. 186:3304-3312.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»